AI drug discovery company
Evaxion
Data as of .
Company facts
-
Founded
2008
-
Headquarters
Denmark (Horsholm)
Latest funding round
- Round
- At-the-market ADS sales
- Date
- Aug 2026
Drugs on the board
- EVX-01
Phase 2 registry
Melanoma
Recent news
-
At-the-market ADS sales: about $2.1M net (681,268 ADSs)
-
To present three-year efficacy data from its Phase 2 trial of personalized cancer vaccine EVX-01
-
Expands its AI-Immunology platform into autoimmune diseases
-
AI-designed vaccine EVX-01 75% ORR in Phase 2 melanoma
-
75% objective response rate in Phase 2 of AI-designed vaccine EVX-01
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.